• American heart journal · Apr 2018

    Comparative Study

    Comparison of adverse event and device problem rates for transcatheter aortic valve replacement and Mitraclip procedures as reported by the Transcatheter Valve Therapy Registry and the Food and Drug Administration postmarket surveillance data.

    • Benjamin Z Galper, David E Beery, Gregory Leighton, and Libbe L Englander.
    • Structural Heart Disease Program, Mid-Atlantic Permanente Medical Group, McLean, VA. Electronic address: Benjamin.z.galper@kp.org.
    • Am. Heart J. 2018 Apr 1; 198: 64-74.

    BackgroundAlthough outcomes data on transcatheter aortic valve replacement (TAVR) and transcatheter mitral valve repair (Mitraclip) are available via the Transcatheter Valve Therapy (TVT) registry, dissemination of TVT data is often delayed. The Food and Drug Administration's Manufacturer and User Facility Device Experience (MAUDE) system collects postmarket outcomes data in public medical device reports. We used natural language processing to compare the event rates for TAVR and Mitraclip in the TVT registry and from MAUDE data.MethodsWe identified all medical device reports related to TAVR and Mitraclip from December 2011 through December 2014. Our primary objective was to demonstrate that event rates in TVT and MAUDE were not significantly different. We also compared TVT event rates for TAVRs performed in 2014 to MAUDE-derived event rates for the Sapien XT and CoreValve devices, both Food and Drug Administration-approved in 2014.ResultsRegression analysis demonstrated close correlation between TVT and MAUDE rates for both TAVR and Mitraclip, with R2 values of 0.86 and 0.77, respectively. The rates for all events except bleeding were not statistically significantly different. We demonstrated similar increased rates of permanent pacemaker implantation in the 2014 TVT and MAUDE data sets consistent with approval of the CoreValve.ConclusionsWe demonstrated that natural language processing technology sorted through raw MAUDE data, allowing identification of the most common events associated with TAVR and Mitraclip procedures, and that MAUDE-derived event rates were not statistically significantly different from TVT event rates. This technology has important public health implications because it improves postmarket surveillance of implantable devices and permits rapid and early dissemination of vital information.Copyright © 2017 Elsevier Inc. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.